Skip to main content
Free access
Research Article
9 December 2016

Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk

Abstract

Aim: Laboratory test (lab) results may be useful to detect incident diabetes in electronic health record and claims-based studies. Research design & methods: Using the Mini-Sentinel distributed database, we assessed the value of lab results added to diagnosis codes and dispensing claims to identify incident diabetes. Results: Inclusion of lab results increased the number of diabetes outcomes identified by 21%. In settings where capture of lab results was relatively complete, the absence of lab results was associated with implausibly low rates of the outcome. Conclusion: Lab results can increase sensitivity of algorithms for detecting diabetes, and missing lab results are associated with much lower rates of diabetes ascertainment regardless of algorithm. Patterns of missing lab results may identify ascertainment bias.

Supplementary Material

File (suppl_figure_1.pdf)

References

1.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl. 1), S62–S69 (2010).
2.
Nichols GA, Desai J, Elston Lafata J et al. Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM Project. Prev. Chron. Dis. 9, 110311 (2012).
3.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1), 1–93 (2005).
4.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8(2), 114–126 (2011).
5.
Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int. Rev. Psychiatry 20, 195–201 (2008).
6.
Goeb JL, Marco S, Duhamel A et al. Metabolic side effects of risperidone in children and adolescents with early-onset schizophrenia. Prim. Care Companion J. Clin. Psych. 10, 486–487 (2008).
7.
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J. Can. Acad. Child Adolesc. Psychiatry 20(3), 218–233 (2011).
8.
Raebel MA, Haynes K, Woodworth TS et al. Electronic clinical laboratory test results data tables: lessons from Mini-Sentinel. Pharmacoepidemiol. Drug Saf. 23(6), 609–618 (2014).
9.
Raebel MA, Shetterly S, Lu CY et al. Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected. Pharmacoepidemiol. Drug Saf. 25(7), 798–814 (2016).
10.
Rosati K, Evans B, McGraw D. HIPAA and common rule compliance in the Mini-Sentinel pilot, white paper (2010). http://mini-sentinel.org/work_products/About_Us/HIPAA_and_CommonRuleCompliance_in_the_Mini-SentinelPilot.pdf.
11.
Department of Health and Human Services, Office of the Secretary. Standards for privacy of individually identifiable health information; final rule. 45 CFR Parts 160 and 164. 2002. Federal Register 53182–53273 (2014). www.ihs.gov/privacyact/documents/privrulepd.pdf.
12.
Dolin P. Pioglitazone, bladder cancer, and detection bias. J. Diabetes 6(2), 193–194 (2014).
13.
Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin. Trials 1(4), 368–376 (2004).